| Amy Lewis Hennessy, MD | |
|
250 River Rd, Manchester, NH 03104-2423 | |
| (603) 668-2020 | |
| (603) 668-0881 |
| Full Name | Amy Lewis Hennessy |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 20 Years |
| Location | 250 River Rd, Manchester, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780892836 | NPI | - | NPPES |
| 93408502 | Other | MD | BC BS |
| 123130 | Other | MD | GEISINGER HEALTH PLAN |
| 019616900 | Medicaid | MD | |
| DH0987 | Other | MD | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0009X | Ophthalmology - Glaucoma Specialist | 17007 (New Hampshire) | Secondary |
| 207W00000X | Ophthalmology | 17007 (New Hampshire) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elliot Professional Services | 6103727920 | 304 |
| The Medical Eye Center Pc | 7315916095 | 9 |
News Archive
To understand both the correlates of protection induced by vaccinations and the necessary immune responses to manage the COVID-19, researchers from Singapore used an alternative method to closely evaluate the kinetics and magnitude of specific T cell responses to SARS-CoV-2 infection. Their work was posted to the bioRxiv* preprint server while awaiting peer review.
A team of researchers from Spain and Switzerland have developed a new model for studying the development of testicular germ cell tumors by transplanting embryonic stem cells into the seminiferous tubules in mouse models, resulting in the development of testicular germ cell tumors (TGCT) that mimic the early stages of TGCT development.
Researchers of the Universitat Politècnica de València and the Universidade Federal do Ceará (Brazil) have completed a study that lays the foundation to obtain apple cubes enriched with probiotics, namely Lactobacillus casei. The work has been published in the most recent edition of the Journal of Functional Foods.
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors.
WHO HIV/AIDS Director Dr Kevin De Cock reported that the number of people receiving HIV antiretroviral therapy in sub-Saharan Africa has surpassed 1 million for the first time, a ten-fold increase in treatment access in the region since December 2003.
› Verified 5 days ago
| Entity Name | Elliot Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285627935 PECOS PAC ID: 6103727920 Enrollment ID: O20040115000634 |
News Archive
To understand both the correlates of protection induced by vaccinations and the necessary immune responses to manage the COVID-19, researchers from Singapore used an alternative method to closely evaluate the kinetics and magnitude of specific T cell responses to SARS-CoV-2 infection. Their work was posted to the bioRxiv* preprint server while awaiting peer review.
A team of researchers from Spain and Switzerland have developed a new model for studying the development of testicular germ cell tumors by transplanting embryonic stem cells into the seminiferous tubules in mouse models, resulting in the development of testicular germ cell tumors (TGCT) that mimic the early stages of TGCT development.
Researchers of the Universitat Politècnica de València and the Universidade Federal do Ceará (Brazil) have completed a study that lays the foundation to obtain apple cubes enriched with probiotics, namely Lactobacillus casei. The work has been published in the most recent edition of the Journal of Functional Foods.
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors.
WHO HIV/AIDS Director Dr Kevin De Cock reported that the number of people receiving HIV antiretroviral therapy in sub-Saharan Africa has surpassed 1 million for the first time, a ten-fold increase in treatment access in the region since December 2003.
› Verified 5 days ago
| Entity Name | The Medical Eye Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225004955 PECOS PAC ID: 7315916095 Enrollment ID: O20040929000647 |
News Archive
To understand both the correlates of protection induced by vaccinations and the necessary immune responses to manage the COVID-19, researchers from Singapore used an alternative method to closely evaluate the kinetics and magnitude of specific T cell responses to SARS-CoV-2 infection. Their work was posted to the bioRxiv* preprint server while awaiting peer review.
A team of researchers from Spain and Switzerland have developed a new model for studying the development of testicular germ cell tumors by transplanting embryonic stem cells into the seminiferous tubules in mouse models, resulting in the development of testicular germ cell tumors (TGCT) that mimic the early stages of TGCT development.
Researchers of the Universitat Politècnica de València and the Universidade Federal do Ceará (Brazil) have completed a study that lays the foundation to obtain apple cubes enriched with probiotics, namely Lactobacillus casei. The work has been published in the most recent edition of the Journal of Functional Foods.
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors.
WHO HIV/AIDS Director Dr Kevin De Cock reported that the number of people receiving HIV antiretroviral therapy in sub-Saharan Africa has surpassed 1 million for the first time, a ten-fold increase in treatment access in the region since December 2003.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Lewis Hennessy, MD 250 River Rd, Manchester, NH 03104-2423 Ph: (603) 668-2020 | Amy Lewis Hennessy, MD 250 River Rd, Manchester, NH 03104-2423 Ph: (603) 668-2020 |
News Archive
To understand both the correlates of protection induced by vaccinations and the necessary immune responses to manage the COVID-19, researchers from Singapore used an alternative method to closely evaluate the kinetics and magnitude of specific T cell responses to SARS-CoV-2 infection. Their work was posted to the bioRxiv* preprint server while awaiting peer review.
A team of researchers from Spain and Switzerland have developed a new model for studying the development of testicular germ cell tumors by transplanting embryonic stem cells into the seminiferous tubules in mouse models, resulting in the development of testicular germ cell tumors (TGCT) that mimic the early stages of TGCT development.
Researchers of the Universitat Politècnica de València and the Universidade Federal do Ceará (Brazil) have completed a study that lays the foundation to obtain apple cubes enriched with probiotics, namely Lactobacillus casei. The work has been published in the most recent edition of the Journal of Functional Foods.
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors.
WHO HIV/AIDS Director Dr Kevin De Cock reported that the number of people receiving HIV antiretroviral therapy in sub-Saharan Africa has surpassed 1 million for the first time, a ten-fold increase in treatment access in the region since December 2003.
› Verified 5 days ago
Ahad A Fazelat, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 250 River Rd, Manchester, NH 03104 Phone: 603-663-2020 Fax: 603-668-0881 | |
Jyotsom Bipin Ganatra, MD MPU Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 250 River Rd, Manchester, NH 03104 Phone: 603-668-2020 Fax: 603-668-0881 | |
Dr. Jason Alan Hall, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 250 River Rd, Manchester, NH 03104 Phone: 603-668-2020 Fax: 603-668-0881 | |
Melissa Mei Yiu Wong, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 764 2nd St, Manchester, NH 03102 Phone: 603-669-3925 | |
Dr. Paul Michael Pender, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1415 Elm St, Nh Eye Associates Pa, Manchester, NH 03101 Phone: 603-669-3925 Fax: 603-669-0380 | |
Anthony J Correnti, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 764 2nd St # Sy, Manchester, NH 03102 Phone: 603-669-3925 Fax: 603-669-0380 | |
David Allen Bellows, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 250 River Rd, Manchester, NH 03104 Phone: 603-668-2020 Fax: 603-668-0881 |